PHARMASPIRE - Volume 12, Issue 4, October- December, 2020

Pages: 152-153

Date of Publication: 10-Jun-2022

Print Article   Download XML  Download PDF

Clinical drug-drug interactions of cardiovascular drugs and their case report

Author: Simranjeet Kaur, Kanwalpreet Kaur, Amandeep Singh, Mohit Sharma

Category: Pharmaceutics

Abstract:

This article deals with multifarious range of drug-drug interactions of all types of cardiovascular drugs (e.g., anti-anginal drugs, antihypertensive drugs, etc.) and their severity therein. This piece of work has been formulated after extensive research among various pharmacy-related literatures and contains inputs from all those works therein. DDI in patients receiving multidrug therapy is a major concern. The aim of the present study was to assess the incidence and risk factors of DDIs in patients admitted in the cardiology unit of a teaching hospital. Heparin and aspirin were the most common drugs responsible for DDIs. Bleeding was the most common clinical consequence found in the population. On assessment of severity of DDIs, the majority of the cases were classified as moderate in severity. Aging, female gender, and increase in concurrent medications were found to be associated with increased DDIs. Patients having these risk factors can be actively monitored during their stay in the cardiology department to identify DDIs.

Keywords: Cardiovascular drugs, drug-drug interactions, adverse drug reactions

References:

1. Blix HS, Viktil KK, Moger TA, Reikvam A. Identification of drug interactions in hospitals--computerized screening vs. bedside recording. J Clin Pharm Ther 2008;33:131-9.

2. Simegn A, Azale T, Addis A, Dile M, Ayalew Y, Minuye B. Youth friendly sexual and reproductive health service utilization among high and preparatory school students in Debre Tabor Town, Northwest Ethiopia: A cross sectional study. PLoS One 2020;15:e0240033.

3. Williams SN, Armitage CJ, Tampe T, Dienes K. Public Perceptions of NonAdherence to COVID-19 Measures by Self and Others in the United Kingdom. New York: medRxiv; 2020.

4. Mateti UV, Rajakannan T, Nekkanti H, Rajesh V, Mallaysamy SR, Ramachandran P. Drug-drug interactions in hospitalized cardiac patients. J Young Pharm 2011;3:329-33.

5. Jönsson AK, Spigset O, Jacobsson I, Hägg S. Cerebral haemorrhage induced by warfarin-the influence of drug-drug interactions. Pharmacoepidemiol Drug Saf 2007;16:309-15.

6. Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 1998;18:1112-20.

7. Das S, Behera SK, Xavier AS, Dharanipragada S, Selvarajan S. Are drug-drug interactions a real clinical concern? Perspect Clin Res 2019;10:62-6.

8. Ho YF, Huang SH, Lin HN. Detecting drug-drug interactions in medication profiles of psychiatric inpatients: A two-stage approach. J Formos Med Assoc 2002;101:294-7.

9. Grymonpre RE, Mitenko PA, Sitar DS, Aoki FY, Montgomery PR. Drugassociated hospital admissions in older medical patients. J Am Geriatr Soc 1988;36:1092-8.

10. Jankel CA, Speedie SM. Detecting drug interactions: A review of the literature. DICP 1990;24:982-9.

11. Jankel CA, McMillan JA, Martin BC. Effect of drug interactions on outcomes of patients receiving warfarin or theophylline. Am J Hosp Pharm 1994;51:661-6.

12. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 2004;329:15-9.

13. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug-drug interactions: A literature review. Pharmacoepidemiol Drug Saf 2007;16:641-51.